» Articles » PMID: 32006199

One-step, Rapid and Green Synthesis of Multifunctional Gold Nanoparticles for Tumor-Targeted Imaging and Therapy

Overview
Publisher Springer
Specialty Biotechnology
Date 2020 Feb 2
PMID 32006199
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Gold nanoparticles (GNPs) have always been used as doxorubicin (DOX) transport vectors for tumor diagnosis and therapy; however, the synthesis process of these vectors is to prepare GNPs via chemical reduction method firstly, followed by conjugation with DOX or specific peptides, so these meth•ods faced some common problems including multiple steps, high cost, time consuming, complicated preparation, and post-processing. Here, we present a one-step strategy to prepare the DOX-conjugated GNPs on the basis of DOX's chemical constitution for the first time. Moreover, we prepare a multifunctional GNPs (DRN-GNPs) with a one-step method by the aid of the reductive functional groups possessed by DOX, RGD peptides, and nuclear localization peptides (NLS), which only needs 30 min. The results of scattering images and cell TEM studies indicated that the DRN-GNPs could target the Hela cells' nucleus. The tumor inhibition rates of DRN-GNPs via tumor and tail vein injection of nude mice were 66.7% and 57.7%, respectively, which were significantly enhanced compared to control groups. One step synthesis of multifunctional GNPs not only saves time, materials, but also it is in line with the development direction of green chemistry, and it would lay the foundation for large-scale applications within the near future. Our results suggested that the fabrication strategy is efficient, and our prepared DRN-GNPs possess good colloidal stability in the physiological system; they are a potentially contrast agent and an efficient DOX transport vector for cervical cancer diagnosis and therapy.

Citing Articles

Nanotechnological Advances in the Diagnosis of Gynecological Cancers and Nanotheranostics.

Keyvani V, Mollazadeh S, Riahi E, Mahmoudian R, Anvari K, Avan A Curr Pharm Des. 2024; 30(33):2619-2630.

PMID: 39021196 DOI: 10.2174/0113816128317605240628063731.


Tackling breast cancer with gold nanoparticles: twinning synthesis and particle engineering with efficacy.

Mal S, Chakraborty S, Mahapatra M, Pakeeraiah K, Das S, Paidesetty S Nanoscale Adv. 2024; 6(11):2766-2812.

PMID: 38817429 PMC: 11134266. DOI: 10.1039/d3na00988b.


Updates on Biogenic Metallic and Metal Oxide Nanoparticles: Therapy, Drug Delivery and Cytotoxicity.

Nikolova M, Joshi P, Chavali M Pharmaceutics. 2023; 15(6).

PMID: 37376098 PMC: 10301310. DOI: 10.3390/pharmaceutics15061650.


Nanotechnology in cervical cancer immunotherapy: Therapeutic vaccines and adoptive cell therapy.

Zhou X, Lian H, Li H, Fan M, Xu W, Jin Y Front Pharmacol. 2023; 13:1065793.

PMID: 36588709 PMC: 9802678. DOI: 10.3389/fphar.2022.1065793.


Enhanced photothermal heating and combination therapy of gold nanoparticles on a breast cell model.

Faid A, Shouman S, Badr Y, Sharaky M BMC Chem. 2022; 16(1):66.

PMID: 36071502 PMC: 9454161. DOI: 10.1186/s13065-022-00859-1.


References
1.
Kang B, Afifi M, Austin L, El-Sayed M . Exploiting the nanoparticle plasmon effect: observing drug delivery dynamics in single cells via Raman/fluorescence imaging spectroscopy. ACS Nano. 2013; 7(8):7420-7. DOI: 10.1021/nn403351z. View

2.
Song Y, Liu D, Cheng Y, Liu M, Ye W, Zhang B . Dual subcellular compartment delivery of doxorubicin to overcome drug resistant and enhance antitumor activity. Sci Rep. 2015; 5:16125. PMC: 4632084. DOI: 10.1038/srep16125. View

3.
Pastan I, Gottesman M . Multiple-drug resistance in human cancer. N Engl J Med. 1987; 316(22):1388-93. DOI: 10.1056/NEJM198705283162207. View

4.
Dulkeith E, Morteani A, Niedereichholz T, Klar T, Feldmann J, Levi S . Fluorescence quenching of dye molecules near gold nanoparticles: radiative and nonradiative effects. Phys Rev Lett. 2002; 89(20):203002. DOI: 10.1103/PhysRevLett.89.203002. View

5.
Tan M, Choong P, Dass C . Review: doxorubicin delivery systems based on chitosan for cancer therapy. J Pharm Pharmacol. 2009; 61(2):131-42. DOI: 10.1211/jpp/61.02.0001. View